Form 4: Iovance Biotherapeutics Executive Friedrich Graf Finckenstein Reports Acquisition of Restricted Stock Units

Chief Medical Officer Friedrich Graf Finckenstein reports acquiring restricted stock units in Iovance Biotherapeutics.

Summary

• On March 1, 2024, Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, acquired 105,470 and 46,875 Restricted Stock Units (RSUs).
• The RSUs represent a contingent right to receive shares of Iovance Biotherapeutics common stock.
• The first set of RSUs (105,470) will vest over three years, with one-third vesting on the one-year anniversary of the grant date and the remaining RSUs vesting in eight equal quarterly installments over the next two years.
• The second set of RSUs (46,875) will vest with 50% on the 6-month anniversary of the grant date and the remaining 50% on the one-year anniversary of the grant date.
• The reporting person will need to be employed with the Issuer on the vesting dates.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral.

Positives

• The acquisition of RSUs by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements, but the vesting schedules of the RSUs extend into the future.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may view the acquisition of RSUs by a key executive as a positive signal.

Key Dates